- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
ProductLife Group Acquires Global Regulatory Outsourcing Company
ProductLife Group (PLG, Paris, France) has announced the acquisition of ELC Group, a Czech Republic-based regulatory consulting firm with 150 employees.
The strategic merger with ELC comes two months after the acquisition of US-based regulatory drug development consultancy DSI and helps to further accelerate the execution of PLG’s strategic plan, BoOst 2023, which aims to make PLG the worldwide leader in regulatory affairs and compliance. The new group will now include more than 600 staff members located in 40 countries.
“This is a landmark acquisition for PLG that complements our domain expertise and brings enhanced capabilities to our solutions, enabling us to provide sustainable business value to our clients. Adding offshore delivery capability in such a key location as India expands our ability to meet this goal,” commented Xavier Duburcq, PLG CEO.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
